» Articles » PMID: 38430460

Urinary Protein and Coagulation-fibrinolysis Indicators in Preeclampsia: Expression and Significance

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

This study investigates the expression and significance of urinary protein and coagulation-fibrinolysis indicators in preeclampsia, categorized into mild preeclampsia (109 cases) and severe preeclampsia (97 cases) based on disease severity. Additionally, 110 patients with gestational hypertension (gestational hypertension group) were included for comparative analysis. General information, laboratory indicators, urinary protein, and coagulation-fibrinolysis indicator levels were collected for each group. Significant differences were observed in blood pressure among groups (P < .05), while uric acid, serum creatinine, aspartate transaminase, alanine transaminase, and triglycerides showed no significant differences (P > .05). Total cholesterol, triglycerides, and low-density Lipoprotein levels in severe preeclampsia were higher than those in mild preeclampsia and gestational hypertension groups, whereas high-density lipoprotein, albumin, and platelet levels were lower in severe preeclampsia. No significant differences were observed in prothrombin time or D-dimer levels among groups (P > .05). Urinary protein, urinary protein quantification, activated partial thromboplastin time, thrombin time, and fibrinogen were identified as influencing factors for adverse maternal and infant outcomes in severe preeclampsia patients. The study concludes that urinary protein and coagulation-fibrinolysis indicators are elevated in preeclampsia, particularly in severe preeclampsia cases, suggesting their potential use as diagnostic influencing factors for severe preeclampsia.

Citing Articles

Urinary protein and coagulation-fibrinolysis indicators in preeclampsia: Expression and significance.

Chen Z, Fang F, Yu X J Clin Hypertens (Greenwich). 2024; 26(4):374-381.

PMID: 38430460 PMC: 11007815. DOI: 10.1111/jch.14789.

References
1.
. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet. 2002; 77(1):67-75. View

2.
Maayeh M, Costantine M . Prevention of preeclampsia. Semin Fetal Neonatal Med. 2020; 25(5):101123. PMC: 8236336. DOI: 10.1016/j.siny.2020.101123. View

3.
Shah D, Khalil R . Bioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia. Biochem Pharmacol. 2015; 95(4):211-26. PMC: 4449835. DOI: 10.1016/j.bcp.2015.04.012. View

4.
Feldstein O, Kovo M, Tal O, Braunstein M, Grinstein E, Schreiber L . The association between abnormal coagulation testing in preeclampsia, adverse pregnancy outcomes, and placental histopathology. Hypertens Pregnancy. 2019; 38(3):176-183. DOI: 10.1080/10641955.2019.1638396. View

5.
Xu C, Li Y, Zhang W, Wang Q . Analysis of perinatal coagulation function in preeclampsia. Medicine (Baltimore). 2021; 100(26):e26482. PMC: 8257867. DOI: 10.1097/MD.0000000000026482. View